Although the ratio of the two isoforms of amyloid-Beta (aB42/40) changes significantly in CSF, the difference in blood is not as large. “In plasma, amyloid levels decrease only about 10-15% ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...